![Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine](https://www.science.org/cms/asset/863a4f2d-2e84-4e33-a123-98cda0f8af8b/aau4711-f1.gif)
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine
![Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine](https://www.science.org/cms/asset/109da0fc-3d63-468e-9788-8f64c4780047/stm.2018.10.issue-461.largecover.jpg)
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals | Science Translational Medicine
![Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. - Abstract - Europe PMC Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6314200/bin/nihms-1003601-f0001.jpg)